CorDx Tyfast SARS-CoV-2/Flu A+B Rapid Antigen Point-of-Care Test is a lateral flow immunoassay intended for in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.

Features and Benefits:
SARS-CoV-2/Flu A+B Rapid POC Combo Antigen Test
Simultaneous testing for acute respiratory infections caused by COVID-19, Flu A, Flu B
Lateral flow immunoassay
Covid-19: Sensitivity 89.6%; Specificity 99.8%
Flu A: Sensitivity 85%; Specificity 99.2%
Flu B: Sensitivity 87.5%; Specificity 99.8%
Nasal swab samples
Delivers results within 10 minutes
No equipment necessary
CLIA Waived Test